Patents Issued in December 15, 2020
-
Patent number: 10864211Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.Type: GrantFiled: December 11, 2017Date of Patent: December 15, 2020Assignee: Merck Sharp & Dohme Corp.Inventors: John S. Debenham, Jason M. Cox, Ping Lan, Zhongxiang Sun, Zhe Feng, Chunrui Sun, W. Michael Seganish, Zhong Lai, Cheng Zhu, Thomas Bara, Murali Rajagopalan, Qun Dang, Hyunjin M. Kim, Bin Hu, Jinglai Hao
-
Patent number: 10864212Abstract: The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.Type: GrantFiled: March 22, 2019Date of Patent: December 15, 2020Assignee: University of Kentucky Research FoundationInventors: Jayakrishna Ambati, Benjamin Fowler
-
Patent number: 10864213Abstract: The invention provides a compound for use in treating or preventing a disease or condition selected from cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, mild pulmonary disease, bronchitis, bronchiectasis, idiopathic bronchiectasis, allergic bronchopulmonary aspergillosis, sinusitis, rhinosinusitis, CFTR-related metabolic syndrome (CRMS), pancreatitis, idiopathic chronic pancreatitis and Sjörgren's syndrome, or for use in preventing male infertility caused by congenital absence of the vas deferens, in a patient by modulating CFTR activity, which compound is 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof.Type: GrantFiled: May 11, 2015Date of Patent: December 15, 2020Assignee: VERONA PHARMA PLCInventors: Katharine Abbott-Banner, John Hanrahan, David Thomas
-
Patent number: 10864214Abstract: A method for healing a hard-to-heal wound including the steps of: topically administering a wound healing composition to a wounded area, wherein the wound healing composition includes, at least one of: (a) a medicament characterized as a calcium channel blocker or pharmaceutically acceptable salts or solvates thereof; (b) a medicament characterized as an alpha-adrenergic antagonist or pharmaceutically acceptable salts or solvates thereof; (c) a medicament characterized as a direct vasodilator or pharmaceutically acceptable salts or solvates thereof; and (d) a medicament characterized as a phosphodiesterase type five inhibitor or pharmaceutically acceptable salts or solvates thereof; and (e) a hemorrheologic agent or pharmaceutically acceptable salts or solvates thereof; (f) a primary dermal penetrating agent or pharmaceutically acceptable salts or solvates thereof: and (g) a topical stimulating agent or pharmaceutically acceptable salts or solvates thereof.Type: GrantFiled: December 4, 2018Date of Patent: December 15, 2020Assignee: Medergo Associates, LLCInventors: Matthew H. Kopacki, Michael J. Torsiello
-
Patent number: 10864215Abstract: The present disclosure relates to methods of treating a vascular malformation in a subject expressing a gain-of-function mutation in a PIK3CA gene comprising administering, to the subject, an effective amount of an agent that inhibits phosphoinositide 3-kinase (“PI3K”).Type: GrantFiled: November 14, 2017Date of Patent: December 15, 2020Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Eulalia Baselga, Pau Castel, Jose T. Baselga
-
Patent number: 10864216Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.Type: GrantFiled: March 5, 2018Date of Patent: December 15, 2020Assignee: WisTa Laboratories, Ltd.Inventors: Colin Marshall, Scott Clunas, John Mervyn David Storey, James Peter Sinclair, Thomas Craven Baddeley, Ahtsham Ishaq, Michael Simpson, Craig Williamson, Barry Alan Wood, Claude Michel Wischik, Charles Robert Harrington, Janet Elizabeth Rickard, David Horsley, Yin Sze Loh, Karrar Ahmad Khan, Christopher Paul Larch
-
Patent number: 10864217Abstract: Provided herein is the use of compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), alone or in combination with other therapeutic agents, in the treatment of human immunodeficiency virus (HIV).Type: GrantFiled: May 24, 2019Date of Patent: December 15, 2020Assignees: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, SALK INSTITUTE FOR BIOLOGICAL STUDIESInventors: Lars Pache, Sumit K. Chanda, Mitchell Dennis Vamos, Nicholas David Peter Cosford, Peter Teriete, John Marlett, Arturo Diaz, John A. T. Young
-
Patent number: 10864218Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.Type: GrantFiled: June 24, 2019Date of Patent: December 15, 2020Assignee: ALLERGAN, INC.Inventor: Patrick M. Hughes
-
Patent number: 10864219Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.Type: GrantFiled: December 14, 2018Date of Patent: December 15, 2020Assignee: The Johns Hopkins UniversityInventors: Alexey Popov, Elizabeth M. Enlow, Hongming Chen, James Bourassa
-
Patent number: 10864220Abstract: This invention discloses applications of desogestrel in the preparation of anti-colon cancer/breast cancer ER-negative Ah receptor-positive products. This invention provides applications for desogestrel in the preparation of products to treat colon cancer and/or breast cancer. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug desogestrel, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that desogestrel has a new use as an anti-colon cancer medication, thus achieving a new purpose for an old drug.Type: GrantFiled: June 30, 2015Date of Patent: December 15, 2020Assignee: SHANGHAI JIAO TONG UNIVERSITYInventors: Yongyong Shi, Zhijian Song
-
Patent number: 10864221Abstract: A neuroprotective mixture includes Phosphocreatine (PCr), Magnesium Gluconate (MgG), and ?-hydroxybutyrate (BHB). The PCR, MgG, and BHB are combined in a 2:1:2 molar ratio of PCr:MgH:BHB. The neuroprotective mixture is a useful preventative and prophylactic supplement, which also can function to extend the post-stroke treatment window.Type: GrantFiled: March 15, 2019Date of Patent: December 15, 2020Assignee: TRICERAPRO HOLDING, LLCInventors: Joseph L. Clark, Todd J. Crocco, Charles L. Rosen, Steven Cutright
-
Patent number: 10864222Abstract: Provided herein are heterocyclic compounds and pharmaceutical formulations that can be used to treat bacterial infections. Also provided herein are methods of making and using the heterocyclic compounds and pharmaceutical formulations.Type: GrantFiled: December 19, 2019Date of Patent: December 15, 2020Assignees: UNIVERSITY OF SOUTH FLORIDA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Yu Chen, Orville Antonio Pemberton, Adam Renslo, Priyadarshini Jaishankar
-
Patent number: 10864223Abstract: The present invention provides improved processes for extracting and preparing lipids from biological sources for use in pharmaceuticals, nutraceuticals and functional foods.Type: GrantFiled: February 10, 2016Date of Patent: December 15, 2020Assignee: Aker BioMarine Antarctic ASInventors: Finn Myhren, Nils Hoem, Asgeir Saebo, Anil R. Oroskar, Asha A. Oroskar, Anantha Krishna Mallia
-
Patent number: 10864224Abstract: The invention relates to a synthetic composition comprising human milk oligosaccharides for use in at least partially restoring the commensal gastrointestinal microbiota and preventing or mitigating antibiotic associated diarrhoea.Type: GrantFiled: November 17, 2016Date of Patent: December 15, 2020Assignee: GLYCOM A/SInventors: Bruce McConnell, Louise Kristine Vigsnæs, David Paul Kronlage
-
Patent number: 10864225Abstract: A SGLT2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, a SGLT2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and/or regional adiposity in an equine animal.Type: GrantFiled: November 28, 2016Date of Patent: December 15, 2020Inventors: Dania Birte Reiche, Laura Johnston, Nicole Mohren
-
Patent number: 10864226Abstract: The present invention relates to a use of microRNA(miR)-188-5p which can be used for treatment of Alzheimer's disease, and the pharmaceutical composition comprising miR-188-5p as an active ingredient of the present invention can inhibit the expression of NRP2 protein when it is added to a subject having Alzheimer's disease, thereby restoring the reduced density of dendritic spines and enhancing synaptic transmission, and thus it can prevent or treat Alzheimer's disease effectively.Type: GrantFiled: April 6, 2017Date of Patent: December 15, 2020Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATIONInventors: Hye Sun Kim, Kihwan Lee, Hyunju Kim
-
Patent number: 10864227Abstract: A heparin structure with increased anticoagulant activity and method of making the same are disclosed. A heparin sample is provided and treated with a heparan sulfate sulfotransferase in an enzymatic reaction to add sulfuryl groups from a sulfuryl group source to the heparin sample, resulting in a heparin structure having above about 8% more 3-O-sulfo groups relative to wild-type bovine intestinal heparin. The added sulfuryl groups modify the heparin structure and increase the sample's binding to antithrombin III and its anticoagulant activity to be more similar and a viable alternative to porcine intestinal heparin. The modified heparin exhibits an anti-FXa activity and an anti-FIIa activity greater than about 180 U/mg, and a ratio of the anti-FXa activity to the anti-FIIa activity of about 0.9 to about 1.1, consistent with U.S. Pharmacopeia (USP) heparin activity specifications.Type: GrantFiled: March 20, 2018Date of Patent: December 15, 2020Assignee: Rensselaer Polytechnic InstituteInventors: Li Fu, Kevin Li, Daisuke Mori, Makoto Hirakane, Jonathan S. Dordick, Robert J. Linhardt
-
Patent number: 10864228Abstract: The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a diffusion-controlled inner coating and an enteric outer coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.Type: GrantFiled: May 24, 2018Date of Patent: December 15, 2020Assignee: Albireo ABInventors: Per-Göran Gillberg, Nils Ove Gustafsson, Nils-Olof Lindberg, Jessica Elversson
-
Patent number: 10864229Abstract: Methods of treating a subject who has chronic tissue ischemia are disclosed. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to result in blood vessel growth in the ischemic tissue. The subject can be diagnosed as having a medical condition that results in persistent or recurring restriction of blood supply to a tissue, for example, peripheral artery disease, diabetes, atherosclerotic cardiovascular disease or defective wound healing. The methods can include the step of identifying a suitable subject.Type: GrantFiled: April 10, 2017Date of Patent: December 15, 2020Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITYInventors: Christopher Kevil, David Lefer, Rakesh Patel
-
Patent number: 10864230Abstract: The present invention pertains to the use of the calcium-sensing receptor (CaSR)-activating nutrients (designated as “CaSR-based nutrients”) for the prevention and/or treatment of diarrheal diseases and inflammation in the gastrointestinal tract. In one embodiment, the current invention is formulated for oral administration. The anti-diarrheal composition of the present invention is useful for treating diarrheal and gastrointestinal inflammatory conditions in infants and young children.Type: GrantFiled: June 4, 2018Date of Patent: December 15, 2020Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventor: Sam Xianjun Cheng
-
Patent number: 10864231Abstract: Botulinum toxin is combined with colloidal silver particles to provide improved compositions for use in medical and cosmetic treatments.Type: GrantFiled: August 28, 2015Date of Patent: December 15, 2020Assignees: American Silver, LLC, Dr. Andrew Willoughby Inc.Inventors: Andrew J. M. Willoughby, Keith William Moeller
-
Patent number: 10864232Abstract: The present invention provides modified natural killer T (NKT) cells, pharmaceutical compositions comprising the modified NKT cells and at least one pharmaceutically acceptable carrier or excipient, and uses of the modified NKT cells. Also disclosed herein are methods for enriching NKT cells and generating the modified natural killer T cells.Type: GrantFiled: April 6, 2016Date of Patent: December 15, 2020Assignee: FULLHOPE BIOMEDICAL CO., LTD.Inventors: Jan-Mou Lee, Chih-Hao Fang, Ya-Fang Cheng, Da-Tsen Wei, Kai-Yuan Jhou
-
Patent number: 10864233Abstract: Methods for treating cardiovascular disorders that include administration of an ECM based composition to damaged cardiovascular tissue in conjunction with a treatment remedy, such as ventricular assistance and transmyocardial revascularization (TMR), which induces enhanced bioremodeling of the damaged cardiovascular tissue and regeneration of new cardiovascular tissue and associated structures with site-specific structural and functional properties.Type: GrantFiled: January 23, 2018Date of Patent: December 15, 2020Assignee: CorMatrix Cardiovascular, Inc.Inventor: Robert G Matheny
-
Patent number: 10864234Abstract: Methods are disclosed for forming bone and/or cartilage in an avian subject. The methods include administering to the avian subject a therapeutically effective amount of a composition comprising avian mesenchymal stem cells and a hydrogel that supports the differentiation of the avian mesenchymal stem cells into cells of an osteogenic and/or condrogenic lineage. In some embodiments, methods are disclosed for repairing a bone defect and preventing infection, such as that associated bone fracture, in an avian subject. The methods include administering locally to the bone defect a composition comprising a therapeutically effective amount of avian mesenchymal stem cells and a hydrogel, such as a methacrylated gelatin hydrogel.Type: GrantFiled: November 4, 2015Date of Patent: December 15, 2020Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventor: Rocky S. Tuan
-
Patent number: 10864235Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.Type: GrantFiled: December 17, 2018Date of Patent: December 15, 2020Assignee: Seres Therapeutics, Inc.Inventors: Matthew R. Henn, Geoffrey von Maltzahn, Anthony Mario D'Onofrio, Kevin Daniel Litcofsky, David Arthur Berry, David N. Cook, Noubar B. Afeyan, John Grant Aunins
-
Patent number: 10864236Abstract: The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.Type: GrantFiled: January 16, 2019Date of Patent: December 15, 2020Assignee: 4D Pharma Research LimitedInventors: George Grant, Angela Margaret Patterson, Imke Mulder, Seanin McCluskey, Emma Raftis
-
Patent number: 10864237Abstract: Lactobacillus-based probiotic compositions for inclusion in microbial-based products. In one instance, the microbial-based product takes the form of an animal feed additive. When used as a feed additive for animals, especially ruminants, and in particular cattle, the following benefits from the composition are noted: (i) improved milk yield in dairy cattle, (ii) improved milk composition in dairy cattle, (iii) increased weight gain-to-feed intake ratio in beef cattle (feed efficiency), and (vi) improved average daily weight gain. Both Lactobacillus strains MB101 having ATCC Accession Number PTA-121710 and MB102 having ATCC Accession Number PTA-121711 are particularly effective at producing these results. Another marked benefit of the compositions when used as an animal feed additive is inhibition of pathogenic growth including E. coli, Salmonella, Clostridium, Staphylococcus and Streptococcus.Type: GrantFiled: November 15, 2019Date of Patent: December 15, 2020Assignee: MICROBIOS, INC.Inventors: Matthew Ryan Garner, Joseph F. Flint
-
Patent number: 10864238Abstract: The present invention relates to a pharmaceutical composition and a food composition for preventing or ameliorating degenerative neurological disease comprising Poria cocos peel extract for preventing, or treating neurodegenerative disorders. Poria cocos peel extract which is the active ingredients contained in the composition of the present invention, has a memory ameliorating activity through inhibiting of acetylcholine esterase and a neuroprotective effect and neuron protection by inhibiting the formation of beta amyloid and tau phosphorylation and promoting NGF production. Thus, the present invention may be useful as a pharmaceutical composition for preventing or treating degenerative neurological diseases, or as a health food for the above purpose.Type: GrantFiled: December 3, 2015Date of Patent: December 15, 2020Assignee: NEUROBO PHARMACEUTICALS, INC.Inventors: Sang Zin Choi, Mi Won Sohn, Hyo Sang Go, Ja Young Ryu, Jin Seok Jeong, Song Hyen Choi, Eun Jin Kim, Young Woong Cho, So Young Kim
-
Patent number: 10864239Abstract: A method of extracting a Kanna plant comprising the steps of harvesting and drying the plant; extracting the alkaloids from the plant in a solvent; filtering the solvent-Kanna plant mixture to remove the solvent and extracted alkaloids from a spent plant matter; drying the spent plant matter; purifying and separating the extracted alkaloids from the solvent; and mixing the purified alkaloids back into the dried spent plant matter. Also, products of the method include vaporizing liquids, medicinal compositions, kief compositions, rolling papers, and filters for tobacco and vaporizing equipment comprising the mixture of the purified alkaloids and the dried spent plant matter produced according to the method. Further, a Kanna plant having a total alkaloid content of 3.5-18%, of which 40% of the total alkaloid content is 0.5-40% mesembrine at a ratio of 2:5 for mesembrine:total alkaloid content.Type: GrantFiled: October 30, 2019Date of Patent: December 15, 2020Assignee: PLANT SYNERGY INC.Inventor: Armand Bytton
-
Patent number: 10864240Abstract: The invention generally relates to a liquid topical pharmaceutical composition used in treating various skin wounds. The composition is characterized by strong moisture absorption and retention capabilities and being able to quickly seal the wound. The composition can resist oxidation, effectively inhibit bacteria and sterilization, protect germinal cells from further damage, eliminate wound swelling and promote wound healing. The pharmaceutical composition can be widely used in the treatment of burn, skin abrasion, laceration, infectious skin ulcer and wound exposure, save dressing and be used in a convenient and highly effective way.Type: GrantFiled: November 29, 2018Date of Patent: December 15, 2020Inventor: Yuanqiao Fu
-
Patent number: 10864241Abstract: Provided herein is technology relating to tomato extracts and particularly, but not exclusively to preparing and using tomato extracts as an anti-hypertensive agent to modulate blood pressure.Type: GrantFiled: December 21, 2017Date of Patent: December 15, 2020Assignee: Provexis Natural Products LimitedInventor: Asim K. Duttaroy
-
Patent number: 10864242Abstract: The present invention discloses a composition for the therapeutic management of male sexual dysfunction and related disorders. Specifically, the invention discloses a composition comprising 60-65% w/w Withania somnifera extract, 12-18% w/w Mucana pruriens extract, 5-10% w/w Coleus forskolii extract, 12-18% w/w Kaempferia parviflora extract, 0.1-2% w/w Piper nigrum extract, for use as an aphrodisiac.Type: GrantFiled: April 17, 2019Date of Patent: December 15, 2020Assignee: SAMI LABS LIMITEDInventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sarang Bani, Anjali Pandey
-
Patent number: 10864243Abstract: The present invention discloses a composition comprising Allium sativum extract standardized to contain not less that 0.3% w/w S-allylcysteine, Beta vulgaris extract standardized to contain not less than 2% w/w nitrates, Nigella sativa extract standardized to contain 0.1%-5% w/w thymoquinone, about 0.01%-10% w/w thymohydroquinone, about 20%-95% w/w fatty acids, about 0.001%-3% w/w ?-hederin or hederagenin, and Terminalia arjuna extract standardized to contain 3% w/w arjunoglucosides for use a prostaglandin transporter inhibitor. The invention also discloses the use of the aforementioned composition in the therapeutic management of hypertension and cardiovascular complications.Type: GrantFiled: June 6, 2019Date of Patent: December 15, 2020Assignee: SAMI LABS LIMITEDInventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sarang Bani, Anjali Pandey
-
Patent number: 10864244Abstract: The present disclosure provides pharmaceutical compositions comprising rationally designed peptide analogs of the p65-TAD binding region of GILZ to selectively sequester activated p65. Structural and functional analyses suggest that select GILZ analog (GA) bind p65-TAD with optimum affinity, exhibit an estimated half minimal lethal dose comparable to known peptide drugs and suppress A?1-42 induced cytotoxicity. Furthermore, the present disclosure provides uses and methods of using the pharmaceutical compositions, and uses and methods of using pharmaceutical formulations comprising the pharmaceutical compositions, for the treatment of neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS).Type: GrantFiled: August 22, 2018Date of Patent: December 15, 2020Assignee: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATIONInventors: Mythily Srinivasan, Debomoy Lahiri
-
Patent number: 10864245Abstract: The invention relates to an isolated peptide for use as a medicament, wherein said peptide has 9 to 30 amino acids and comprises or consists of an amino acid sequence according to SEQ ID NO 1 (VMAPRTLXL), wherein X is an amino acid with a hydrophobic side chain (A, I, L, F, V, P, G), preferably V, L, I or F. The invention further relates to the peptide of the invention for use as a medicament to expand and/or activate NKG2C+ natural killer (NK) cells. The invention further relates to the peptide of the invention for use in the treatment and/or prevention of a medical condition associated with pathogenic cells expressing HLA-E and a peptide comprising an amino acid sequence according to SEQ ID NO 1 or 2. Additionally, the invention relates to a genetically modified virus encoding a peptide comprising or consisting of a polypeptide of the invention for use as a medicament to expand and/or activate NKG2C+ natural killer (NK) cells.Type: GrantFiled: March 15, 2019Date of Patent: December 15, 2020Assignee: DEUTSCHES RHEUMA-FORSCHUNGSZENTRUM BERLINInventors: Chiara Romagnani, Timo Rückert, Quirin Hammer
-
Patent number: 10864246Abstract: New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.Type: GrantFiled: May 13, 2019Date of Patent: December 15, 2020Assignees: Centro De Investigación En Alimentación Y Desarrollo, A.C. (CIAD)Inventors: Belinda Vallejo Galland, Aarón Fernando González Córdova, Jóse Carlos Rodríguez Figueroa
-
Patent number: 10864247Abstract: New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.Type: GrantFiled: May 13, 2019Date of Patent: December 15, 2020Assignees: Centro De Investigación En Alimentación Y Desarrollo, A.C. (CIAD)Inventors: Belinda Vallejo Galland, Aarón Fernando González Córdova, Jóse Carlos Rodríguez Figueroa
-
Patent number: 10864248Abstract: Compositions and kits including an agent that inhibits the interaction between Disabled-2 and mutant CFTR proteins, optionally in combination with a CFTR corrector, CFTR potentiator, CAL inhibitor, mucolytic, anti-inflammatory agent or a combination thereof are provided as are methods for preventing or treating cystic fibrosis.Type: GrantFiled: November 11, 2015Date of Patent: December 15, 2020Assignee: TRUSTEES OF DARTMOUTH COLLEGEInventor: Dean R. Madden
-
Patent number: 10864249Abstract: Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.Type: GrantFiled: June 11, 2019Date of Patent: December 15, 2020Assignees: MELINTA THERAPEUTICS, INC., ABBVIE INC.Inventors: Adel Rafai Far, Gopal Krishna, Min Ding, Sanjay R. Chemburkar, Carl M. Knable, James P. Petzel, Julie J. Pruyne, Douglas M. Reamer
-
Patent number: 10864250Abstract: Liquid vancomycin containing compositions having extended shelf life are disclosed. The compositions contain vancomycin or a pharmaceutically acceptable salt thereof, a polyol such as glycerol, and lactic acid or a lactate. The compositions are ready to use and easily transferred into larger parenteral solutions prior to administration to patients in need thereof.Type: GrantFiled: July 16, 2019Date of Patent: December 15, 2020Assignee: SCIDOSE PHARMA LLCInventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 10864251Abstract: The present invention provides a peptide derived from the extracellular domain of syndecan-1 that inhibits angiogenesis.Type: GrantFiled: January 18, 2019Date of Patent: December 15, 2020Assignee: Wisconsin Alumni Research FoundationInventors: Alan C. Rapraeger, DeannaLee M. Beauvais
-
Patent number: 10864252Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for synovial sarcoma X Breakpoint (SSX)-2. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.Type: GrantFiled: October 29, 2018Date of Patent: December 15, 2020Assignee: The United States of Americans represented by the Secretary, Department of Health and Human ServicesInventors: Richard A. Morgan, Nachimuthu Chinnasamy, Steven A. Rosenberg
-
Patent number: 10864253Abstract: Provided herein are peptides and peptide analogs that have tissue protective activities. The peptides and peptide analogs are useful in preventing and treating a variety of diseases and disorders associated with tissue damage.Type: GrantFiled: April 28, 2017Date of Patent: December 15, 2020Assignee: Araim Pharmaceuticals, Inc.Inventors: Michael Brines, Anthony Cerami
-
Patent number: 10864254Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.Type: GrantFiled: May 1, 2019Date of Patent: December 15, 2020Assignee: Rani Therapeutics, LLCInventor: Mir Imran
-
Patent number: 10864255Abstract: The present invention comprises a method to diminish and/or eliminate atherosclerotic plaques, in mammals, through direct and indirect treatment of these plaques, in situ, using suitable substances which are capable of lipid removal, primarily through hydrolysis, either by a catalytic or stoichiometric process, wherein the substance targets receptors in and/or on the cell which lead to uptake into the lysosome. Such substances used to diminish and/or eliminate atherosclerotic plaques are generally comprised of lipid hydrolyzing proteins and/or polypeptides.Type: GrantFiled: February 13, 2017Date of Patent: December 15, 2020Assignee: Children's Hospital Medical CenterInventors: Gregory A. Grabowski, Hong Du
-
Patent number: 10864256Abstract: Provided herein are klotho polypeptide compositions and methods for improving cognitive function in an individual comprising treatment of with klotho polypeptides.Type: GrantFiled: January 23, 2020Date of Patent: December 15, 2020Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: Dena Dubal
-
Patent number: 10864257Abstract: The present invention relates to the use of plasminogen in the dissolution of fresh and old thrombus. Compared with other existing thrombolytic drugs, the plasminogen of the present invention can specifically dissolve thrombus without causing side effects such as bleeding. The drug of the present invention also has the advantages of dissolving both fresh and old thrombus, with a long half-life and controllable thrombolytic strength. Therefore, plasminogen may become a brand-new strategy for dissolving thrombus in vivo.Type: GrantFiled: December 16, 2016Date of Patent: December 15, 2020Assignee: TALENGEN INTERNATIONAL LIMITEDInventor: Jinan Li
-
Patent number: 10864258Abstract: Attenuated Toxoplasma gondii mutants and methods using the same as vaccines in the prevention or treatment pancreatic cancer are provided.Type: GrantFiled: April 15, 2014Date of Patent: December 15, 2020Assignee: TRUSTEES OF DARTMOUTH COLLEGEInventors: David J. Bzik, Barbara A. Fox, Kiah L. Sanders
-
Patent number: 10864259Abstract: Provided herein are methods and compositions for the treatment of melanoma using anti-tumor immune cells treated with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein).Type: GrantFiled: November 8, 2018Date of Patent: December 15, 2020Assignee: TAIGA BIOTECHNOLOGIES, INC.Inventors: Yosef Refaeli, Brian C. Turner, Gregory Alan Bird
-
Patent number: 10864260Abstract: The present invention relates to new protein compositions, methods for producing said protein compositions, pharmaceutical compositions comprising said protein compositions and methods for treating infections caused by Neospora caninum. In particular, the present invention relates to a protein composition comprising the proteins specified in Table A in an amount of at least about 2 times (fold change) higher than the same protein present in the whole tachyzoite, as calculated by quantitative label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS).Type: GrantFiled: October 28, 2016Date of Patent: December 15, 2020Assignee: UNIVERSIDAD COMPLUTENSE DE MADRIDInventors: Javier Regidor Cerrillo, David Arranz Solís, Esther Collantes Fernández, Gema Álvarez García, Luis Miguel Ortega Mora